Mesenchymal Stem Cell–Sourced Exosomes as Potentially Novel Remedies for Severe Dry Eye Disease
Journal of Ophthalmology · 2025-01 · 2025 (1)
DOI: 10.1155/joph/5552374 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Ophthalmology, online erschienen am 10.01.2025. Verfasst von Carl Randall Harrell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Regenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, Florida, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu.
Abstract (Originalsprache)
Severe dry eye disease (DED) is an inflammatory condition characterized by a lack of sufficient moisture or lubrication on the surface of the eye, significantly impacting the quality of life and visual function. Since detrimental immune response is crucially responsible for the development and aggravation of DED, therapeutic agents which modulate phenotype and function of eye‐infiltrated inflammatory immune cells could be used for the treatment of severe DED. Due to their potent immunomodulatory properties, mesenchymal stem cells (MSCs) represent potentially new remedies for the treatment of inflammatory eye diseases. The majority of MSC‐sourced bioactive factors are contained within MSC‐derived exosomes (MSC‐Exos), nano‐sized extracellular vesicles which, due to their nanosize dimension and lipid envelope, easily by pass all biological barriers in the body and deliver their cargo directly into the target immune cells. MSC‐Exos contain a variety of bioactive proteins (growth factors, immunoregulatory molecules, cytokines, and chemokines) lipids, and microRNAs (miRNAs) which affect viability, proliferation, phenotype, and function of eye‐infiltrated immune cells. Accordingly, MSC‐Exos may modulate the progression of inflammatory eye diseases, including DED. Therefore, in this review article, we summarized the current knowledge regarding molecular and cellular mechanisms which were responsible for trophic, anti‐inflammatory, immunoregulatory, and regenerative properties of MSC‐Exos in the treatment of severe DED. For this purpose, an extensive literature review was carried out in February 2024 across several databases (Medline, Embase, and Google Scholar), from 2000 to the present. Eligible studies delineated molecular and cellular mechanisms responsible for the MSC‐Exos–based modulation of immune cell–driven eye inflammation in DED, and their findings were analyzed in this review. Results obtained in these studies demonstrated beneficial effects of MSC‐Exos in the treatment of severe DED, paving the way for their future clinical use in ophthalmology. Trial Registration: ClinicalTrials.gov identifier: NCT04213248 , NCT06475027 , NCT06543667 , NCT05738629
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biology, Regenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, Florida, USA.
- Department of Anatomy, Institute of Anatomy, University of Bern, Baltzerstrasse 2, Bern 3012, Switzerland.
- Departments of Psychology, Center for Research on Harmful Effects of Biological and Chemical Hazards, Faculty of Medical Sciences University of Kragujevac, 69 Svetozara Markovica Street, Kragujevac 34000, Serbia.
- Departments of Genetics, Microbiology and Immunology, Center for Research on Harmful Effects of Biological and Chemical Hazards, Faculty of Medical Sciences University of Kragujevac, 69 Svetozara Markovica Street, Kragu…
- Department of Biology, Faculty of Pharmacy Novi Sad, Trg Mladenaca 5, Novi Sad 21000, Serbia.
ORCID-Profile: Vladislav Volarevic
Förderung
- Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu
Zitieren
APA
Randall Harrell, C., Djonov, V., Volarevic, A., Arsenijevic, A., & Volarevic, V. (2025). Mesenchymal Stem Cell–Sourced Exosomes as Potentially Novel Remedies for Severe Dry Eye Disease. Journal of Ophthalmology, 2025(1). https://doi.org/10.1155/joph/5552374
Vancouver
Randall Harrell C, Djonov V, Volarevic A, Arsenijevic A, Volarevic V. Mesenchymal Stem Cell–Sourced Exosomes as Potentially Novel Remedies for Severe Dry Eye Disease. Journal of Ophthalmology. 2025;2025(1). doi:10.1155/joph/5552374
BibTeX
@article{RandallHarrell2025,
author = {Randall Harrell, Carl and Djonov, Valentin and Volarevic, Ana and Arsenijevic, Aleksandar and Volarevic, Vladislav},
title = {Mesenchymal Stem Cell–Sourced Exosomes as Potentially Novel Remedies for Severe Dry Eye Disease},
journal = {Journal of Ophthalmology},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/joph/5552374}
}
EUVIMED